FindTrial
Sign In

CER-001

DRUG5 trials

Sponsors

Cerenis Therapeutics, SA

Conditions

Acute Coronary SyndromeAcute Coronary SyndromesFamilial HypoalphalipoproteinemiaHeterozygous Familial HypercholesterolemiaHomozygous Familial Hypercholesterolemia

Phase 2

Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial
CompletedNCT01201837
Cerenis Therapeutics, SAAcute Coronary Syndrome
Start: 2011-03-31End: 2013-03-31Updated: 2014-03-03
Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects
CompletedNCT01412034
Cerenis Therapeutics, SAHomozygous Familial Hypercholesterolemia
Start: 2011-11-30End: 2014-08-31Updated: 2015-08-18
Exploratory Study of Plaque Regression
CompletedNCT01515241
Cerenis Therapeutics, SAHeterozygous Familial Hypercholesterolemia
Start: 2012-01-31End: 2012-05-31Updated: 2014-03-03
CER-001 Atherosclerosis Regression ACS Trial
CompletedNCT02484378
Cerenis Therapeutics, SAAcute Coronary Syndromes
Start: 2015-08-31End: 2016-12-31Updated: 2019-02-11

Phase 3

CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases
TerminatedNCT02697136
Cerenis Therapeutics, SAFamilial Hypoalphalipoproteinemia
Start: 2015-12-31End: 2018-12-21Updated: 2025-07-22

Related Papers

Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial
European Heart Journal2014-04-29251 citations